Updated Date: Dec 24, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence)

We examined dose and other factors associated with decreased pain intensity among patients initiating BUP/NX for OUD. (Source: Drug and Alcohol Dependence)

Aims: The favorable clinical characteristics and improved treatment outcomes for prescription opioid dependent (POD) patients, and modest severity of withdrawal symptoms with buprenorphine/naloxone (bup/nx), have led physicians to offer detoxification with bup/nx for POD patients. We sought to determine whether bup/nx stabilization followed by detoxification (DTX) or maintenance (MTN) leads to greater reduction in illicit opioid use and treatment completion among POD patients treated in primary care. (Source: Drug and Alcohol Dependence)

This study extends the comparison of diversion and abuse rates between buprenorphine sublingual formulations. (Source: Drug and Alcohol Dependence)

Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence)

Aims: The buprenorphine/naloxone (Bup/Nal)combination for the treatment of opioid dependence is available in two forms – sublingual film and tablet. Recent studies demonstrated that treatment with film leads to improved treatment retention and lower healthcare costs. In March 2013 generic tablets appeared on the market. A budget impact model was built to compare health care expenditures based on current market shares of Bup/Nal film and generic Bup/Nal tablet. (Source: Drug and Alcohol Dependence)

Aims: The favorable clinical characteristics and improved treatment outcomes for prescription opioid dependent (POD) patients, and modest severity of withdrawal symptoms with buprenorphine/naloxone (bup/nx), have led physicians to offer detoxification with bup/nx for POD patients. We sought to determine whether bup/nx stabilization followed by detoxification (DTX) or maintenance (MTN) leads to greater reduction in illicit opioid use and treatment completion among POD patients treated in primary care. (Source: Drug and Alcohol Dependence)

This study extends the comparison of diversion and abuse rates between buprenorphine sublingual formulations. (Source: Drug and Alcohol Dependence)

Aims: To assess whether response to Cognitive Behavioral Therapy (CBT) differed between primarily prescription opioid users (POU) and primarily heroin users (HU) receiving primary care buprenorphine/naloxone (BUP) treatment with physician management (PM). (Source: Drug and Alcohol Dependence)